Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to eight newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to eight newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards, effective December 1, 2025, consist of non-statutory stock options to purchase an aggregate of 51,600 shares and restricted stock units representing an aggregate of 17,066 shares. The stock options carry a $11.71 exercise price (closing Nasdaq price on the effective date), have a 10-year term, and vest over four years (25% after one year, then monthly over three years). The restricted stock units vest over three years in equal annual installments, with the first vesting on December 1, 2026. Awards are subject to the award agreements and the inducement plan terms.
Details
News Market Reaction – OCUL
On Dec 5, the day this news came out, OCUL closed 1.21% above the previous close.
Data tracked by StockTitan Argus for the Dec 5 session.
Key Figures
- Stock options granted
- 51,600 shares
- Non-statutory stock options under 2019 Inducement Stock Incentive Plan
- RSUs granted
- 17,066 shares
- Restricted stock unit awards to eight non-executive employees
- Exercise price
- $11.71 per share
- Equal to Nasdaq Global Market closing price on Dec 1, 2025
- Option term
- 10 years
- Non-statutory stock option duration
- Option vesting period
- 4 years
- 25% after one year, then monthly over three years
- RSU vesting period
- 3 years
- RSUs vest in equal annual installments
- First RSU vest date
- Dec 1, 2026
- Initial annual installment vesting date
- Employees receiving awards
- 8 employees
- Newly hired non-executive employees
Historical Context
-
First patient randomized in HELIOS-3 Phase 3 NPDR registrational trial.
-
Participation in November and December healthcare investor conferences.
-
Inducement equity awards to a new non-executive employee under 2019 plan.
-
Q3 results with lower revenue, wider net loss, higher R&D spending.
-
SOL-R Phase 3 trial reached target randomization of 555 subjects.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non-statutory stock options financial
restricted stock unit financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to eight newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity awards were granted effective as of December 1, 2025, and consist of non-statutory stock options to purchase up to an aggregate of 51,600 shares of Ocular’s common stock and restricted stock unit awards representing the right to receive an aggregate of 17,066 shares of Ocular’s common stock. The stock options have an exercise price of
The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and non-proliferative diabetic retinopathy (NPDR).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.
Explore the Company’s new corporate branding and follow the Company on its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.